- New York NY, US - Boston MA, US Akiko Koide - New York NY, US Linxiao Chen - Doylestown PA, US Eric Elenko - Boston MA, US Aleksandra Filipovic - London, GB Joseph Bolen - Boston MA, US
International Classification:
C07K 16/28 A61P 35/00 C07K 16/06 A61P 37/06
Abstract:
Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
- New York NY, US - Boston MA, US Akiko Koide - New York NY, US Linxiao Chen - Doylestown PA, US Eric Elenko - Boston MA, US Aleksandra Filipovic - London, GB Joseph Bolen - Boston MA, US
International Classification:
C07K 16/28 A61P 35/00 C07K 16/06 A61P 37/06
Abstract:
Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.
Combined Cancer Therapy Of Anti-Galectin-9 Antibodies And Chemotherapeutics
- New York NY, US - Boston MA, US Akiko KOIDE - New York NY, US Linxiao CHEN - New York NY, US Aleksandra FILIPOVIC - London, GB Eric ELENKO - Boston MA, US Joseph BOLEN - Boston MA, US
International Classification:
C07K 16/28 A61P 37/06 A61P 35/00
Abstract:
Combined therapy for a solid tumor, comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g, G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.
- New York NY, US - Ghent, BE Akiko KOIDE - New York NY, US Nadia LELOUP - New York NY, US Julien OURY - New York NY, US Karen SILENCE - Ghent, BE Roeland VANHAUWAERT - Ghent, BE Christophe BLANCHETOT - Ghent, BE
International Classification:
C07K 16/28 A61P 21/04
Abstract:
The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.
- New York NY, US - Boston MA, US Akiko KOIDE - New York NY, US Linxiao CHEN - New York NY, US Aleksandra FILIPOVIC - London, GB Eric ELENKO - Boston MA, US Joseph BOLEN - Boston MA, US
Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.
- New York NY, US - Boston MA, US Akiko KOIDE - New York NY, US Linxiao CHEN - New York NY, US Aleksandra FILIPOVIC - London, GB Eric ELENKO - Boston MA, US Joseph BOLEN - Boston MA, US
International Classification:
C07K 16/28 A61P 35/04 A61P 35/00
Abstract:
Disclosed herein are methods for treating solid tumors (e.g., pancreatic adenocarcinoma (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC)), or Cholangiocarcinoma and others), including, but not limited to, metastatic tumors, using an anti-Galectin-9 antibody.
Selective And Noncovalent Inhibitors Of Oncogenic Ras Mutants
- New York NY, US Kai Wen Teng - Flushing NY, US Akiko Koide - New York NY, US Takamitsu Hattori - West New York NJ, US
International Classification:
C07K 14/47 A61P 35/00
Abstract:
Provided are proteins or peptides, which may be referred to as monobodies. Fusion proteins and proteolysis targeting chimeras (PROTACs) comprising the proteins or peptides are also provided. Also provided are compositions of the proteins or peptides of the present disclosure, as well as compositions of fusion proteins and compositions of PROTACs. Methods of treating an individual in need of treatment are also provided. The methods may be to treat an individual suffering from or suspected of having KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers. A method may be for inhibiting ERK activation and/or proliferation of KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers.
- New York NY, US - Boston MA, US Akiko KOIDE - New York NY, US Linxiao CHEN - New York NY, US Aleksandra FILIPOVIC - London, GB Eric ELENKO - Boston MA, US Joseph BOLEN - Boston MA, US
International Classification:
G01N 33/574 C07K 16/28
Abstract:
Disclosed herein are methods for identifying a subject as having certain solid cancers such as breast cancer, colorectal colon cancer, or non-small cell lung cancer, or being at risk for the cancer based on the level of Galectin-9 in a biological sample (e.g., a blood sample) from a subject suspected of having the solid cancer.
Sumitomo Mitsui Banking Corporation
Senior Credit Officer
Mizuho Bank Nov 2011 - Aug 2017
Vice President
Daiwa Capital Markets America Mar 2006 - Apr 2010
Vice President
Itochu Financial Services, Inc Jun 2004 - Mar 2006
Assistant Vice President
Morgan Stanley 1998 - 2001
Fixed Income Specialist
Education:
National University of Singapore 2010 - 2011
Masters, Master of Laws
New York University School of Law 2010 - 2011
Masters, Master of Laws
University of North Carolina at Chapel Hill 2002 - 2004
Master of Business Administration, Masters, Corporate Finance
Osaka University
Bachelors, Bachelor of Law
Skills:
Corporate Finance Hedge Funds Fixed Income Alternative Investments Securities Capital Markets Financial Markets Structured Products Corporate Law Series 7
Nyu Langone Medical Center
Research Assistant Professor of Medicine
Education:
The University of Tokyo
Doctorates, Doctor of Philosophy, Philosophy
Skills:
Protein Purification Western Blotting Molecular Biology Pcr Molecular Cloning Biochemistry Protein Chemistry Protein Expression Elisa Cell Biology Life Sciences Cell Culture Research